



Supplementary Figure 1 Correlations of serum qHBcrAg with other serum parameters among different time and different treatment in all patients at baseline (A), in all patients at week 48 (B), in the entecavir group at week 48 (C), and in the peginterferon group at week 48 (D).

Supplementary Table 1 Baseline characteristics of patients treated with ETV or Peg-IFN

Characteristics	Entecavir (N=109)	Peg-IFN (N=30)	P
Age, years, median (range)	32 (19-62)	26.5 (19-39)	0.045
Sex (male/female)	78/31	18/12	0.363
HBV genotype, n (%)			
B	18 (16.5%)	10 (33.3%)	
C	93 (85.3%)	20 (66.7%)	
Baseline ALT levels, U/ml, mean \pm SD	179.07 \pm 124.69	167.48 \pm 70.45	0.208
Baseline serum HBV DNA level, log ₁₀ IU/ml, mean \pm SD	7.61 \pm 0.95	7.57 \pm 1.10	0.833
Baseline serum pgRNA level, log ₁₀ copies/ml, mean \pm SD	7.92 \pm 1.17	7.74 \pm 1.18	0.736
Baseline ihHBV cccDNA level, copies/cell	20.25 \pm 8.25	33.80 \pm 13.79	0.154
Baseline ihHBV DNA level, copies/cell	350.19 \pm 45.60	455.50 \pm 109.95	0.248
Baseline Serum HBsAg level, log ₁₀ IU/ml, mean \pm SD	3.84 \pm 0.68	3.78 \pm 0.64	0.508
Baseline Serum HBeAg level, log ₁₀ S/CO, mean \pm SD	2.51 \pm 0.79	2.42 \pm 0.92	0.471
Baseline HBcrAg, log ₁₀ U/ml, mean \pm SD	5.24 \pm 1.07	5.38 \pm 1.22	0.294

HBV: hepatitis B virus; ALT: alanine transaminase; ihHBV: intrahepatic hepatitis B virus; cccDNA: covalently closed circular DNA; HBsAg: hepatitis B surface antigen; HBeAg: hepatitis B e-antigen; HBcrAg: hepatitis B core-related antigen; SD: standard deviation.